Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
Open Access
- 19 May 2020
- preprint content
- Published by Research Square Platform LLC
Abstract
Background: The prevalences of diabetes mellitus and hypertension, both of which are components of metabolic syndrome, are known to be increased among patients with multiple myeloma (MM), but remain undetermined among patients with smoldering MM (SMM). Methods: Changes in various components of metabolic syndrome were investigated during the follow-up of patients with either MM or SMM compared to healthy controls. The data of 153 patients (105 with MM and 48 with SMM) and 138 controls were accessed from our medical center’s records between 2008-2015. We analyzed the patients’ data at diagnosis (baseline) and after 1, 3, and 5 years of follow-up. Results: Patients with SMM had a significantly higher prevalence of diabetes, hypertension, and dyslipidemia at baseline compared to controls. A multivariate Cox regression analysis revealed a higher risk to develop dyslipidemia after 1, 3, and 5 years of follow-up among the SMM patients. The MM patients had a higher risk to develop diabetes after 1 year, hypertension after 5 years, and dyslipidemia after 1, 3, and 5 years of follow-up. Conclusions: These data demonstrate that patients with SMM and those with MM are more prone to develop various components of metabolic syndrome, and they stress the importance of following-up metabolic syndrome components in both groups of patients.Keywords
This publication has 43 references indexed in Scilit:
- Statin use and risk of multiple myeloma: An analysis from the cancer research networkInternational Journal of Cancer, 2017
- Management of multiple myeloma in older adults: Gaining ground with geriatric assessmentJournal of Geriatric Oncology, 2016
- Hyperlipidemic myeloma: review of 53 casesAnnals of Hematology, 2009
- Cholesterol levels in patients with multiple myelomaAnnals of Hematology, 2007
- Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literatureCancer, 2007
- Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the diseaseCancer Chemotherapy and Pharmacology, 2003
- C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes MellitusJama-Journal Of The American Medical Association, 2001
- Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort studyThe Lancet, 1999
- Cytokine Network in Human Multiple MyelomaHematology/Oncology Clinics of North America, 1992
- Interleukin‐6 is the major regulator of acute phase protein synthesis in adult human hepatocytesFEBS Letters, 1989